^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    STAMP inhibitor

    Related drugs:
    7d
    ASCERTAIN: A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients (clinicaltrials.gov)
    P=N/A, N=37, Completed, Novartis Pharmaceuticals
    New trial • Real-world evidence
    |
    ABL1 T315I
    |
    Scemblix (asciminib)
    8d
    ASCIRLI: Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines (clinicaltrials.gov)
    P=N/A, N=98, Not yet recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto
    New trial • Real-world evidence
    |
    Scemblix (asciminib)
    9d
    Asciminib With or Without Sildenafil for Brain Tumors (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Washington University School of Medicine | Trial completion date: Nov 2027 --> Mar 2028 | Initiation date: Apr 2026 --> Aug 2026 | Trial primary completion date: Oct 2027 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)
    |
    Scemblix (asciminib) • sildenafil
    15d
    PONTHIAC: Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib (2025-521126-15-00)
    P1/2, N=30, Not yet recruiting, Grupo Espanol De Leucemia Mieloide Cronica (GELMC)
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Iclusig (ponatinib) • Scemblix (asciminib)
    20d
    Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML (clinicaltrials.gov)
    P3, N=8, Terminated, Sarit Assouline | N=164 --> 8 | Trial completion date: Dec 2025 --> Jul 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jul 2025; Insufficient patient accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    imatinib • Scemblix (asciminib)
    22d
    CABL001I12202: Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia. (2025-522138-29-00)
    P1/2, N=14, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Scemblix (asciminib)
    27d
    Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Venclexta (venetoclax) • cytarabine • Blincyto (blinatumomab) • idarubicin hydrochloride • Scemblix (asciminib) • fludarabine IV • Neupogen (filgrastim)
    29d
    CABL001I12202: Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia. (2025-522138-29-00)
    P1/2, N=7, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Scemblix (asciminib)
    1m
    Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2035 --> Jun 2036 | Trial primary completion date: Jan 2033 --> Jul 2033
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule)
    |
    ABL1 T315I • ABL2 fusion
    |
    cytarabine • Blincyto (blinatumomab) • vincristine • Scemblix (asciminib)
    1m
    ASC2ADHERE: A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany (clinicaltrials.gov)
    P=N/A, N=380, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Scemblix (asciminib)
    1m
    Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Novartis Pharmaceuticals | Initiation date: Mar 2026 --> Jul 2026
    Trial initiation date
    |
    ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule)
    |
    ABL1 T315I • ABL2 fusion
    |
    cytarabine • Blincyto (blinatumomab) • vincristine • Scemblix (asciminib)
    1m
    ASCENdANT: Asciminib in HER2+ Breast Cancer Brain Metastases (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, Duke University | Initiation date: Feb 2026 --> Jul 2026
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • Scemblix (asciminib)